Russell I Jon, Larson Alice A
Department of Medicine, Division of Clinical Immunology and Rheumatology, University Clinical Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA.
Rheum Dis Clin North Am. 2009 May;35(2):421-35. doi: 10.1016/j.rdc.2009.06.005.
The characteristic presenting complaint of patients with fibromyalgia syndrome (FMS) is chronic widespread allodynia. Research findings support the view that FMS is an understandable and treatable neuropathophysiologic disorder. The pain of FMS is often accompanied by one or more other manifestations, such as affective moods, cognitive insecurity, autonomic dysfunction, or irritable bowel or bladder. Growing evidence suggests that this is a familial disorder with many underlying genetic associations. New findings from brain imaging and polysomnography imply that FMS may be a disorder of premature neurologic aging. A conceptual model at the molecular level is proposed to explain many of the observed features of FMS. The model can also explain anticipated responses to FDA approved pharmacologic therapies.
纤维肌痛综合征(FMS)患者的典型主诉是慢性广泛性痛觉过敏。研究结果支持这样一种观点,即FMS是一种可理解且可治疗的神经病理生理障碍。FMS的疼痛常伴有一种或多种其他表现,如情感情绪、认知不安全感、自主神经功能障碍或肠易激综合征或膀胱易激综合征。越来越多的证据表明,这是一种具有许多潜在遗传关联的家族性疾病。脑成像和多导睡眠图的新发现表明,FMS可能是一种神经早衰性疾病。本文提出了一个分子水平的概念模型来解释FMS的许多观察到的特征。该模型还可以解释对美国食品药品监督管理局(FDA)批准的药物治疗的预期反应。